Article info
PDFHepatology
Original article
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
- Correspondence to Professor Gamal Shiha, Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Dakahlia 35516, Egypt; g_shiha{at}hotmail.com
Citation
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
Publication history
- Received December 20, 2017
- Revised March 7, 2018
- Accepted March 29, 2018
- First published April 17, 2018.
Online issue publication
March 07, 2019
Article Versions
- Previous version (7 March 2019).
- Previous version (7 March 2019).
- Previous version (7 March 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/